This review highlights the challenges in defining major bleeding in acute coronary syndrome and emphasizes the importance of predicting and managing bleeding risks associated with antithrombotic therapies.
Answers are grounded in this paper and cite their sources.
Bleeding definitions in ACS remain inconsistent; review leaves open standardized endpoints for antithrombotic trials.
Acute coronary syndrome forms the vast majority of cases faced in daily cardiology clinical practice. It is usually managed by antiplatelates, antithrombotics and anticoagulants, all of which increase the risk of bleeding with associated increment in morbidity and mortality. Data gained from many studies and registries all over the world try to explore the magnitude of such problem as well as predictors and management. The definition of major bleeding in acute coronary syndrome is a dilemma by itself, as different definitions have led to inconsistency in its reported prevalence and magnitude of sequelae. Predicting the occurrence of major bleeding may help in saving lives, improving outcomes and cost-savings by preventing it. In this review, we try to explore these issues based on data extracted from large numbers of trials, studies and registries.
No takes yet. Share an insight, caveat, or question.
Shakir et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: